Medicare Opens Door to CBD in Landmark Federal Pilot Program

WASHINGTON, D.C. – April 01, 2026 – In a move that could reshape the landscape for cannabinoid-based therapies in the United States, the U.S. Centers for Medicare & Medicaid Services (CMS) have officially launched a groundbreaking pilot program that opens the door for Medicare beneficiaries to access hemp-derived CBD products.

The initiative, which commenced today, has immediately drawn the attention of major players in the CBD industry. Among the first to publicly declare its intentions is High Tide Inc., a Canadian cannabis enterprise, which announced its U.S. subsidiary, NuLeaf Naturals, is actively pursuing participation as a key supplier. This development signals a pivotal moment where federally supported healthcare models are beginning to formally intersect with the burgeoning CBD market.

A New Incentive for Healthcare

The program, officially titled the "Substance Access Beneficiary Engagement Incentive" (BEI), is an initiative of the CMS Innovation Center, an agency division tasked with testing new healthcare payment and service delivery models. It is not a broad, universal benefit but a targeted pilot available to specific healthcare organizations.

Initially, participation is open to Accountable Care Organizations (ACOs) under the ACO REACH Model and oncology practices participating in the Enhancing Oncology Model (EOM). These organizations can now elect to create plans that furnish eligible hemp-derived products to their aligned Medicare beneficiaries. Under the program's framework, patients can receive up to US$500 worth of these products annually at no personal cost.

Crucially, CMS will not be directly paying for the CBD. The cost is borne by the participating healthcare organizations, which can use the incentive as a tool to potentially improve patient outcomes and manage symptoms within their value-based care arrangements. CMS has also indicated the program could expand to its Long-term Enhanced ACO Design (LEAD) Model as early as January 1, 2027.

The primary objective, as described by federal officials, is to generate real-world clinical data. By facilitating the use of CBD in structured, physician-guided settings, CMS aims to build an evidence base that could inform future decisions on broader coverage and full reimbursement.

A Presidential Push and Shifting Policies

The BEI pilot did not emerge from a vacuum. It is a direct follow-through on a U.S. Presidential Executive Order signed by President Donald J. Trump on December 18, 2025. That order directed federal agencies to advance the rescheduling of cannabis and improve patient access to CBD products.

At the heart of the order was a directive for the Attorney General to expedite the administrative process of moving cannabis from Schedule I to Schedule III of the Controlled Substances Act. A Schedule III classification, while not full legalization, would formally recognize cannabis as having accepted medical use and lower potential for abuse. Such a move is widely expected to remove significant barriers to medical research and provide major tax relief to state-legal cannabis businesses, which would become exempt from the restrictive IRS code Section 280E.

As part of that announcement, CMS Administrator Dr. Mehmet Oz confirmed the Innovation Center would launch this pilot. The move represents a significant step by the executive branch to align federal health policy with evolving views on cannabis and its derivatives, even as the legislative landscape remains complex.

The Race to Supply a New Market

The launch of the BEI program has created an immediate and potentially lucrative new market, and companies are moving quickly to establish themselves as trusted suppliers. High Tide's subsidiary NuLeaf Naturals, a Denver-based company founded in 2014, is a prime example of a firm positioning itself for this opportunity.

"The launch of the CMS pilot program is a historic moment for the U.S. CBD industry and, most importantly, for the millions of Medicare beneficiaries who may now have access to hemp-derived cannabinoid therapies at no cost to themselves," said Raj Grover, Founder and Chief Executive Officer of High Tide, in a public statement.

NuLeaf's competitive advantage hinges on its established quality and compliance infrastructure. The company operates out of cGMP-certified and FDA-registered manufacturing facilities, with USDA Organic certification reportedly in process. Its product portfolio includes THC-free and broad-spectrum CBD formats that appear designed to meet the pilot's stringent requirements. Grover added that the company has already begun engaging with ACOs and oncology programs to become a supplier, expressing confidence that the program could become a "meaningful growth driver" for the business.

High Tide and NuLeaf are also founding members of the National Compassionate Care Council (NCCC), an industry coalition that includes other major players like Tilray Inc., Medterra CBD, and Lazarus Naturals. The existence of this council suggests a coordinated industry effort to engage with policymakers and a competitive field of well-established companies likely vying for similar supplier roles.

Strict Rules for Patient Access

While the program is a significant step, it is governed by strict rules and safeguards. To be eligible, products must be federally legal hemp items containing no more than 0.3% delta-9 THC. Inhalable products like vapes are explicitly forbidden, as are oral products with more than 3 mg of THC per serving.

Participating healthcare organizations must submit a detailed implementation plan to CMS for approval, outlining the specific products, dosing information, and beneficiary eligibility criteria they will use. Clinicians must determine that the use of CBD is safe and appropriate for each individual patient, who must be over 18 and not pregnant or breastfeeding.

For now, access is limited to beneficiaries aligned with the five ACOs that have already submitted plans and any other organizations that join the pilot in the coming months. The program's success, and its potential expansion from a data-gathering exercise into a fully-fledged Medicare benefit, will hinge on the quality of the evidence it generates in the months and years ahead.